Gene Therapy for Critical Limb Ischemia: Per Aspera ad Astra

Curr Gene Ther. 2022;22(3):214-227. doi: 10.2174/1566523221666210712185742.

Abstract

Peripheral artery diseases remain a serious public health problem. Although there are many traditional methods for their treatment using conservative therapeutic techniques and surgery, gene therapy is an alternative and potentially more effective treatment option especially for "no-option" patients. This review treats the results of many years of research and application of gene therapy as an example of treatment of patients with critical limb ischemia. Data on successful and unsuccessful attempts to use this technology for treating this disease are presented. Trends in changing the paradigm of approaches to therapeutic angiogenesis are noted: from viral vectors to non-viral vectors, from gene transfer to the whole organism to targeted transfer to cells and tissues, from single-gene use to combination of genes; from DNA therapy to RNA therapy, from in vivo therapy to ex vivo therapy.

Keywords: Critical limb ischemia; angiogenesis; gene therapy; peripheral artery; problems and perspectives; therapeutic genes; vectors.

Publication types

  • Review

MeSH terms

  • Chronic Limb-Threatening Ischemia*
  • Genetic Therapy / methods
  • Genetic Vectors / genetics
  • Genetic Vectors / therapeutic use
  • Humans
  • Ischemia* / genetics
  • Ischemia* / therapy
  • Neovascularization, Pathologic
  • Neovascularization, Physiologic / genetics